Emerging Insights into Tislelizumab-Induced Lichenoid Drug Eruption and Cutaneous Squamous Cell Carcinoma: A Rare but Critical Immune-Related Adverse Event
The expanding frontier of immunotherapy has brought substantial breakthroughs in cancer treatment, harnessing the power of immune checkpoint inhibitors (ICIs) to transform the prognosis for many patients. Among these, tislelizumab, a novel programmed cell death protein-1 (PD-1) inhibitor, has garnered significant attention for its efficacy in treating various malignancies. However, as with many immune-modulating therapies, its potential to induce rare but serious dermatologic immune-related adverse events (irAEs) demands urgent and thorough examination. A recent study published in BMC Geriatrics details a particularly rare phenomenon: the occurrence of a lichenoid drug eruption coupled with cutaneous squamous cell carcinoma (cSCC) in the context of tislelizumab therapy. This finding not only deepens our understanding of the cutaneous complications linked with ICIs but also raises pivotal questions about the mechanisms underlying these dual pathological events.
Programmed death-1 (PD-1) inhibitors like tislelizumab function by blocking PD-1 receptors on T cells, thereby preventing their inactivation by tumor cells expressing PD-L1. This unleashes an immune-mediated attack against the cancer but simultaneously predisposes patients to immune dysregulation. Dermatologic manifestations are among the most common irAEs observed with PD-1 blockade, ranging from mild rashes to severe lichenoid reactions. Lichenoid drug eruption represents a T-cell-mediated hypersensitivity reaction that histopathologically mimics idiopathic lichen planus but is triggered by pharmacologic agents. The immunobiology involves cytotoxic CD8+ T cell infiltration targeting basal keratinocytes, culminating in interface dermatitis characterized by vacuolar degeneration and apoptotic keratinocytes.
What makes the case reported by Zhang especially compelling and clinically significant is the concomitant development of cutaneous squamous cell carcinoma alongside the lichenoid eruption. Cutaneous squamous cell carcinoma, the second most common skin cancer, is typically associated with cumulative UV exposure and chronic skin inflammation. However, its emergence in the context of immune checkpoint inhibition is paradoxical and poorly understood. The dual presentation suggests a complex interplay between immune activation and tolerance breakdown, potentially fostering a microenvironment conducive to neoplastic transformation amidst chronic immune-mediated tissue injury.
Pathophysiological insights gleaned from this case reveal that sustained immune activation against keratinocytes, although intended as an anti-tumoral mechanism, can result in collateral epithelial damage. This damage may promote an aberrant wound healing response and genome instability in skin cells, thereby facilitating oncogenesis. Furthermore, PD-1 blockade may inadvertently impair peripheral tolerance checkpoints that normally suppress autoinflammatory sequelae, paving the way for both lichenoid tissue injury and tumor development. The dichotomy of immune activation generating therapeutic benefit versus pathologic sequelae underscores the delicate balance clinicians must navigate.
Clinically, the lichenoid drug eruption presented as violaceous, polygonal papules and plaques predominantly distributed across the trunk and extremities, accompanied by pruritus. Histological examination typically reveals a dense band-like lymphocytic infiltrate at the dermoepidermal junction with basal keratinocyte damage—a hallmark of lichenoid dermatitis. The temporal association with tislelizumab administration alongside lesion biopsy confirmed the diagnosis. Surgical excision of the suspicious nodular lesion revealed well-differentiated cutaneous squamous cell carcinoma, thereby substantiating the rare but critical co-occurrence.
This unusual coexistence prompts a reassessment of patient risk stratification and monitoring protocols during anti-PD-1 therapy. It behooves clinicians to maintain heightened vigilance for atypical cutaneous presentations and consider early dermatologic consultation and biopsy even for lesions that might initially appear benign or inflammatory. Additionally, these findings advocate for integration of dermatologic assessment into routine oncological care pathways, especially given cutaneous signs may precede or coincide with more sinister transformations.
Therapeutically, management of such irAEs presents a formidable challenge. Standard approaches to lichenoid drug eruptions involve topical or systemic corticosteroids to reduce inflammation; however, immunosuppression must be judiciously balanced against potential compromise of anticancer immunity. For the neoplastic lesion, surgical excision remains first-line, but the underlying immunotherapy context demands multidisciplinary evaluation. In some instances, temporary cessation or modification of ICI therapy may be necessary to mitigate further adverse events while maintaining oncologic control.
On the molecular level, future investigations are warranted to delineate the signaling pathways and immune cell subsets responsible for triggering both lichen planus–like eruptions and cutaneous carcinogenesis under PD-1 blockade. Such studies could reveal biomarkers predictive of susceptibility to cutaneous irAEs and identify potential targets to prevent or ameliorate these toxicities without abrogating anti-tumor efficacy. For example, exploration of cytokine profiles, T-cell receptor repertoires, and keratinocyte gene expression changes during therapy could yield transformative insights.
This case also opens broader discourse on the paradoxical oncogenic potentials inherent in immunotherapies. While these agents aim to boost immune surveillance and tumor eradication, certain off-target effects might inadvertently provide a selective pressure or inflammatory milieu fostering secondary malignancies. Understanding this paradox is essential as the indications for ICIs continue to expand dramatically across cancer types and patient demographics.
Moreover, the demographic aspects, as reported, reveal that the patient was elderly, underscoring the need for tailored monitoring in geriatric oncology populations who may experience different toxicity profiles due to immunosenescence and comorbidities. The interplay between age-related immune changes and irAEs remains an emerging field necessitating comprehensive research to optimize outcomes and safety.
In addition to clinical vigilance, patient education on early recognition of dermatologic symptoms is paramount. Empowering patients to report new skin changes promptly can facilitate early diagnosis and intervention, mitigating morbidity. Integrative care involving oncologists, dermatologists, pathologists, and immunologists is essential to address these multifaceted complications effectively.
In conclusion, the rare but profound nexus of tislelizumab-induced lichenoid drug eruption and cutaneous squamous cell carcinoma delineated in this study heralds an important paradigm shift in recognizing and managing cutaneous irAEs from immune checkpoint inhibition. It emphasizes the bidirectional impact of immune modulation—capable of therapeutic triumph yet vulnerable to unintended tissue pathology and tumorigenesis. As immunotherapy continues revolutionizing cancer care, expanding our mechanistic understanding and clinical acumen surrounding irAEs remains pivotal to fully harness these potent agents’ benefits while safeguarding patient quality of life. Continued research, collaborative clinical vigilance, and patient-centered strategies will undoubtedly shape the next frontier in precision immuno-oncology.
Subject of Research:
The study investigates immune-related adverse events, specifically focusing on the dermatological manifestation of lichenoid drug eruption induced by the PD-1 inhibitor tislelizumab and its rare association with cutaneous squamous cell carcinoma.
Article Title:
Tislelizumab-induced lichenoid drug eruption and cutaneous squamous cell carcinoma: a rare dermatologic immune-related adverse event
Article References:
Zhang, X. Tislelizumab-induced lichenoid drug eruption and cutaneous squamous cell carcinoma: a rare dermatologic immune-related adverse event. BMC Geriatr (2026). https://doi.org/10.1186/s12877-025-06660-8
Image Credits: AI Generated
DOI: 10.1186/s12877-025-06660-8
Keywords:
Tislelizumab, immune checkpoint inhibitor, PD-1 blockade, lichenoid drug eruption, cutaneous squamous cell carcinoma, immune-related adverse event, dermatology, immunotherapy toxicity, skin cancer, immune dysregulation
